李军民，主任医师，博士研究生导师，现任上海交通大学医学院附属瑞金医院血液科主任，中华医学会血液学分会常委，上海医学会血液学分会主委。

血液系统恶性肿瘤的发病机制及临床治疗。

上海交通大学博士

上海交通大学医学院附属瑞金医院血液科主任，中华医学会血液学分会常委，上海医学会血液学分会主委。

中国民主建国会第十二次全国代表大会代表。

中国民主建国会第十二届中央委员会委员

上海市第十二、十三届政协委员

国家健康科普专家库成员

中华医学会血液学分会常委

上海医学会血液学分会主委

学术杂志审稿人

《上海医学》审稿人

学术著作编委

《脐带血造血干细胞移植与伦理原则》编委

2019年教育部科学研究优秀成果奖（科学技术）二等奖

2020年12月，被上海民建授予“民建全国优秀会员”称号。

2024年6月24日，由李军民等组成的《上海交通大学医学院附属瑞金医院血液病转化医学研究创新团队》荣获2023年度国家科技进步奖创新团队。

负责科技部重点专项、国家自然基金面上项目

1. Zi-Zhen Xu, Wan-Bin Fu, Zhen Jin, Pei Guo, Wen-Fang Wang & Jun-Min Li. Reactive Oxygen Species Mediate Oridonin-Induced Apoptosis through DNA Damage Response and Activation of JNK Pathway in Diffuse Large B cell Lymphoma. Leukemia & Lymphoma 2015.

2. Kai Qing, Zhen Jin, Wanbin Fu, Wenfang Wang, Zhao Liu, Xiaoyang Li, Zizhen Xu and Junmin Li. Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma. Journal of Hematology & Oncology. 2016 Aug 23;9(1):72. doi: 10.1186/s13045-016-0303-0.

3. Xiaoyang Li, Yunxiang Zhang, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015 Jan;94(1):57-63.

4. Xiaoyang Li, Hongming Zhu, et al. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia. Acta Haematol. 2016;135(4):217-23.

5. Xiaoyang Li, Yu Zheng, et al. Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China. Acta Haematol. 2017 May 18;137(4):209-213.

6. Hongming Zhu, Jiong Hu, Xiaoyang Li, et al. All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis. Br J Haematol.

7. Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, Zhang YX, Wang Y, Dou HB, Zhang WJ, Zhu J, Liang AB, Li JM, Hu J. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017 Dec;31(12):2761-2770. doi: 10.1038/leu.2017.130.

8. Chen L, Guo P, Zhang Y, Li X, Jia P, Tong J, Li J. Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells. Leukemia research. 2017 Sep;60:44-52. doi: 10.1016/j.leukres.2017.06.007.

9. Zhu H, Hu J, Chen L, Zhou W, Li X, Wang L, Zhao X, Zhang Y, Zhao H, Wang A, Chen Y, Sun H, Chen Q, Chen Y, Zhao W, Mi J, Shen Z, Wang Z, Chen Z, Chen S, Li J. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016 Sep 15;128(11):1525-8.

10. Zhen Jin, Kai Qing, Yuan Ouyang, Zhao Liu, Wenfang Wang, Xiaoyang Li, Zizhen Xu and Junmin Li. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma. Journal of Experimental & Clinical Cancer Research (2016) 35:52.

11. Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, Zhu H, Mao Y, Xu Z, Li J. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. 2018 Aug;97(8):1327-1335. doi: 10.1007/s00277-018-3368-8.

12. Xu ZZ, Shen JK, Zhao SQ, Li JM. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Jun; 9(6):1451-1460. doi: 0.1080/10428194.2017. 379077

《瑞金医院血液科疑难病例讨论集》